Echidna ancestors lived watery lifestyles like platypuses 100 million years ago
They are also very different from each other.
The platypus is well adapted for a semi-aquatic lifestyle, spending up to 20 hours a day swimming in Australian waterways to forage for freshwater invertebrates. Echidnas, on the other hand, live entirely on land. They are widely distributed across Australia and New Guinea, and adapted for feeding on termites, ants and earthworms.
How did these differences emerge? Some researchers think echidnas evolved from a swimming, platypus-like ancestor. This hypothesis is based on evidence from aspects of their genes and anatomy, and from hypotheses about their evolutionary history.
However, this idea is controversial because fossil evidence for such a profound evolutionary transformation has been lacking – until now.
In our study published today in PNAS, we gleaned new data from a 108-million-year-old mammal humerus (arm bone), found 30 years ago at Dinosaur Cove, Victoria, by a team from Museums Victoria.
This arm bone, from a species called Kryoryctes cadburyi, belongs to an ancestral monotreme – a semi-aquatic burrower like the platypus. Our findings support the hypothesis that land-living echidnas evolved from a swimming ancestor.
Kryoryctes lived during the Age of Dinosaurs (the Mesozoic), when monotremes and monotreme relatives were more common than they are today. Glimpses of this past diversity are found in the fossil record in southern Victoria and Lightning Ridge, New South Wales.
Nevertheless, Australian Mesozoic mammal fossils are exceedingly rare, and mostly consist of teeth and jaws. Kryoryctes is the only one known from a limb bone, which provides significant information about its identity, relationships and lifestyle.
In order to test the evolutionary relationships of Kryoryctes, we added it to a broader data set of 70 fossil and modern mammals. From there, we calculated an evolutionary tree. This showed Kryoryctes is an ancestral monotreme.
We also compared the external shape of the Kryroryctes humerus bone to living monotremes. These analyses indicated the bone is more like those of echidnas, rather than platypuses.
But it was a different story on the inside. When we looked at the internal structure of the Kryoryctes humerus with several 3D scanning techniques, we uncovered microscopic features of this arm bone that were actually more like those of the platypus.
Such tiny features inside bones yield crucial clues about the lifestyle of an animal. Numerous previous studies link bone microstructure in mammals and other tetrapods (four-limbed animals) with their ecology.
Using the wealth of data available for living mammals, we compared characteristics of the Kryoryctes humerus microstructure to those in platypuses, echidnas and 74 other mammal species.
These analyses confirmed that the Kryoryctes humerus has internal bone features found in semi-aquatic burrowing mammals (such as the platypus, muskrat and Eurasian otter), rather than land-living burrowing mammals such as the echidna.
This discovery suggests that a semi-aquatic lifestyle is ancestral for all living monotremes. It also suggests the amphibious lifestyle of the modern platypus had its origins at least 100 million years ago, during the Age of Dinosaurs.
In this scenario, the modern platypus lineage has retained the ancestral semi-aquatic burrowing lifestyle for more than 100 million years. Echidnas would have reverted to a land-based way of life more recently.
For echidnas, a return to land appears to have resulted in adaptations such as their long bones becoming lighter, as shown in our study.
They possibly also lost several other features more useful for spending time in the water rather than on land, including the loss of a long tail, reduction of webbing between fingers and toes, reduction of the duck-like bill to a narrow beak, and a reduced number of electroreceptors on that beak.
However, precisely when this evolutionary transformation occurred is not yet known. The answer must wait until early echidna fossils are found – so far, nothing definitive has turned up anywhere.
The modern habitats of monotremes are increasingly under threat from environmental degradation, interactions with humans and feral predators, and climate change. This is especially true for platypuses. To ensure the survival of this ancient lineage, we need to better understand how their unique features evolved and adapted.
This article is republished from The Conversation. It was written by: Sue Hand, UNSW Sydney; Camilo López-Aguirre, University of Toronto; Laura A. B. Wilson, Australian National University, and Robin Beck, University of Salford
Read more:
1 billion years ago, a meteorite struck Scotland and influenced life on Earth
Here's how to make your backyard safer and cooler next summer
How human connections shaped the spread of farming among ancient communities
Sue Hand receives funding from the Australian Research Council
Laura A. B. Wilson receives funding from the Australian Research Council
Robin Beck receives funding from the UK's National Environmental Research Council, and the Australian Research Council.
Camilo López-Aguirre does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Miami Herald
3 days ago
- Miami Herald
Massive sleep study reveals surprising cost of going to bed late
As an avid Oura user, I'm no stranger to *slightly* obsessing over sleep data. I've tracked my deep sleep, REM cycles, HRV, and recovery scores like a mini scientist in a silk sleep mask. I've timed workouts based on my readiness score. When it comes to the link between sleep and performance, I'm not new here. But even with all that tracking and optimization, this new study got my attention. Researchers looked at millions of nights of sleep-over 6 million to be exact-and what they found was something most of us (myself included) tend to overlook. It's not just about how much you sleep. Related: FDA eliminates 52 food standards in sweeping deregulation move It's about when. And more specifically: what happens when you go to bed later than usual. The impact? Subtle at first. But if you're trying to be consistent with your workouts, boost your energy, or just feel better, those late nights might be holding you back. Even if you're still getting 7 to 8 hours of sleep. That's what makes this study different. Because this time, we're not just talking about sleep duration. We're talking about timing-and how it can affect your body and behavior the very next day. The study, published in PNAS, looked at over 6 million nights of sleep data from nearly 26,000 adults using wearable fitness trackers. Specifically, over 19,000 WHOOP users and nearly 6,000 Fitbit device users. Here's what they found: people who went to bed earlier were more likely to exercise the next day. And the difference? Bigger than you'd think. For example, compared to those who went to sleep around 1 a.m., people who consistently went to bed at 9 p.m. logged 28 more minutes of moderate-to-vigorous physical activity (MVPA) the next day. Even more surprising? People who slept less overall, but went to bed earlier, often exercised more than those who slept longer but went to bed later. In other words, timing beat out total sleep when it came to getting people moving. I spoke with Dr. Mark Czeisler, Resident Physician at Brigham and Women's Hospital and Clinical Fellow at Harvard Medical School, who co-authored the study led by Josh Leota, a Research Fellow at Monash University. Related: These clean food brands are rightfully challenging the FDA He explained why bedtime and not just sleep time matters: "People got the most intense exercise when they preserved their usual sleep amount, but went to bed earlier than they typically do," he said. "That suggests these health behaviors aren't competing with each other. They're best thought of as working in concert." Think about it: if you're staying up late to finish one more episode or scroll TikTok, you could be trading away the energy and motivation you'll need tomorrow. Dr. Czeisler also noted that early sleepers are more likely to get in their workouts before the day gets busy. Morning routines tend to be more reliable-and that consistency matters. While this study tracked people living their normal lives-not under lab conditions-it's truly a big moment for sleep and fitness tech. And it supports something companies like WHOOP, Fitbit, Apple Watch and Oura have been saying for years: when you sleep matters just as much as how much you sleep. The WHOOP data came from users who were already pretty active-averaging 90 minutes of MVPA daily. But the researchers confirmed the same trend in a broader group, using Fitbit data from the NIH's All of Us program. Even people who weren't exercising much still saw a difference. Earlier bedtimes meant more movement the next day. As Dr. Czeisler put it: "The way to guarantee exercise is really to protect the morning. And so going to bed earlier, you know, lends itself to doing that." So if you're trying to get consistent with your workouts, improve your energy, or just build better habits, maybe start by looking at the clock. Going to bed a little earlier might be the simplest, most powerful performance tool you're not using yet. Protect your mornings, people! I know I do... Related: Watch out Fitbit and Apple Watch, Amazon has entered the chat The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.


Newsweek
4 days ago
- Newsweek
Doctor Raises Concerns Over Medical Cannabis Use With Cancer Treatment
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Despite its growing popularity among cancer patients for managing symptoms like nausea, pain and reduced appetite, a new study has warned that the use of medicinal cannabis could make immunotherapy less effective. This is the warning of Australian medical cannabis advocate Dr. Ben Jansen, whose newly-published review paper poses the question: "Are cannabinoids with cancer immunotherapy contributing to early death?" "As both a physician involved in the medicinal cannabis industry and an advocate for patient care, I find the discussion and patient informed consent around this interaction critical," Jansen wrote in his study. "Three key studies on this topic offer preliminary data suggesting a potential reduction in immunotherapy efficacy from cannabis use," he continued. "Though the results remain limited and controversial, warranting caution and additional research." Medical marijuana over official looking subscription document. Medical marijuana over official looking subscription document. thegoodphoto/Getty Images The first study looked into patients receiving the immunotherapy drug nivolumab for advanced cancers, including lung cancer, renal cell carcinoma and melanoma. It compared those on nivolumab alone (89 patients) and those on both nivolumab and cannabis (51 patients). The findings, Jansen noted, showed a significantly lower treatment response rate in patients using cannabis than in those on just nivolumab (15.9 vs. 37.5 percent.) The analysis excluded patients with advanced disease with survival of less than two months. "This suggests that patients using cannabis were approximately three times more likely to have a poor response to immunotherapy. Notably, cannabis use did not significantly impact progression-free survival or overall survival," Jansen wrote. Building on this, the second study compared 34 patients prescribed both immunotherapy and cannabis with 68 patients receiving the cancer treatment alone. That study found that tumors tended to take less than three-and-a-half months to grow or spread in the patients taking cannabis, as compared to more than a year for patients on immunotherapy alone. It also found the median overall survival time for cannabis users was 6.4 months compared to 28.5 months for non-users. A colourful illustration representing immune cells and white blood cells. A colourful illustration representing immune cells and white blood cells. quantic69/Getty Images It should be noted that both studies had inherent limitations—including small sample sizes and a focus on inhaled cannabis, rather than the orally-administered versions Jansen notes is favored in his experience with patients. Jansen added: "Factors such as smoking and other lifestyle elements, which heavily influence cancer risk and treatment outcomes, should be carefully considered when assessing cannabis' role in immunotherapy efficacy and cancer progression, and when interpreting the studies." The third study looked at 105 patients with tumors developing in solid organs—e.g. the breast, lung or prostate—receiving immune checkpoint inhibitors, and cannabis use primarily in the form of prescribed dronabinol. (Immune checkpoint inhibitors are a form of immunotherapy treatment that works by blocking proteins that prevent the immune system from attacking cancer cells.) Cannabis use was associated with significantly worse outcomes in patients receiving immunotherapy, including a shorter median overall survival time (6.7 vs 17.3 months), a reduced progression-free survival tune (4.8 vs 9.7 months) and a markedly lower disease control rate (10.7 percent vs 37.7 percent) compared with non-users. "Notably, these negative outcomes were most evident in white patients, raising the possibility of ethnicity-related pharmacogenetic variability in cannabinoid metabolism or immune response," Jansen wrote. Other potentially important factors like performance status, comorbidities and socio-economic status may have also been unaccounted for, and though tobacco was more common among cannabis users, it may still have influenced outcomes. Dropper with medical cannabis CBD hemp oil for oral use. Dropper with medical cannabis CBD hemp oil for oral use. 24K-Production/Getty Images "One of the challenges in interpreting these studies is the inherent complexity of cannabis as a therapeutic agent," wrote Jansen. Past research, Jansen notes, has found that cannabis can suppress the immune system through its active compounds: CBD, THC and other minor cannabinoids. At the same time, however, studies undertaken both in vitro and in living organisms have suggested that cannabinoids can both kill cancer cells and stop from spreading. "These findings hold particular relevance for patients considering, or currently using, medical cannabis during immunotherapy," the doctor said. "As medical practitioners, we must weigh the benefits of cannabis in managing cancer-related symptoms (such as pain, nausea and anorexia) against its potential to compromise treatment efficacy." "While cancer has a promising role in supportive cancer care, these early findings support careful consideration when patients are concurrently undergoing immunotherapy." Jansen emphasized how important it is that clinicians ensure patients are well informed of potential interactions, particularly until we have a clearer understanding of the situation, and has called for more thorough research and trials. "Future studies should aim to control for variables such as cancer type, cannabis dosage, socio-economic status and patient lifestyle factors, particularly tobacco use, which may confound results," he concluded. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about cancer? Let us know via health@ References Bar-Sela, G., Cohen, I., Campisi-Pinto, S., Lewitus, G. M., Oz-Ari, L., Jehassi, A., Peer, A., Turgeman, I., Vernicova, O., Berman, P., Wollner, M., Moskovitz, M., & Meiri, D. (2020). Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers, 12(9), Article 9. Hadid, T., Biedny, A., Mamdani, H., Azmi, A., Kim, S., Jang, H., Uprety, D., Al Hallak, M. N., & Sukari, A. (2024). Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors. Therapeutic Advances in Vaccines and Immunotherapy, 12, 25151355241309095. Jansen, B. (2025). Are cannabinoids with cancer immunotherapy contributing to early death? A call for caution and further study. New Zealand Medical Journal, 138(1619). Taha, T., Meiri, D., Talhamy, S., Wollner, M., Peer, A., & Bar‐Sela, G. (2019). Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. The Oncologist, 24(4), 549–554.


Bloomberg
5 days ago
- Bloomberg
Water Utilities Are Using Solar Panels to Cut Evaporation Losses
Every year, about 1,400 gigaliters of water evaporates from dams and reservoirs across arid Australia, enough to fill Sydney Harbour three times, according to researchers at Deakin University. To reduce this loss, Australian utilities are turning to floating solar installations on lakes and reservoirs. Covering and cooling a large part of the surface of bodies of water with panels reduces evaporation, while also generating electricity. In a country where climate change is making conditions even hotter and drier, and where fresh water is scarce, solutions like this are becoming more attractive.